Comparative Pharmacology
Head-to-head clinical analysis: ADHANSIA XR versus DEXAMPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADHANSIA XR versus DEXAMPEX.
ADHANSIA XR vs DEXAMPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adhansia XR is a central nervous system (CNS) stimulant. The mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully known, but it is thought to involve blockade of norepinephrine and dopamine reuptake into presynaptic neurons, increasing their levels in the synaptic cleft. This enhances attention and reduces impulsivity.
Dextroamphetamine is a central nervous system stimulant that increases extracellular dopamine and norepinephrine levels by blocking their reuptake and promoting release from presynaptic terminals.
Methylphenidate hydrochloride extended-release: Oral, 18-72 mg once daily in the morning.
5-10 mg orally once daily in the morning, maximum 20 mg/day.
None Documented
None Documented
Mean terminal elimination half-life is 7.5 hours (range 5-10 hours) following oral administration, allowing twice-daily dosing.
Terminal elimination half-life 10–13 hours in adults (7–8 hours in children). Longer in alkaline urine (up to 20 hours) due to reduced renal tubular reabsorption.
Primarily renal (78% as unchanged drug), with 10% biliary/fecal elimination.
Renal: ~90% as unchanged drug and metabolites (primarily deaminated metabolites); fecal/biliary <2%.
Category C
Category C
CNS Stimulant
CNS Stimulant